$1.14/ day, billed weekly
Cancel anytime

(Ads Free, Unlimited access)

NO CREDIT CARD REQUIRED

DERM

Journey Medical Corp (DERM)

$3.91

Delayed price

PASS

Time period over

ALL
YEAR
MONTH
WEEK

Upturn Advisory Summary

12/31/2024: DERM (2-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

AI Based Fundamental Rating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Analysis of Past Performance

Type Stock

Historic Profit -5.25%

Avg. Invested days 33

Today’s Advisory PASS

Upturn Star Rating

Upturn Advisory Performance

3.0

Stock Returns Performance

1.0

Profits based on simulation

Last Close 12/31/2024

Key Highlights

Company Size Small-Cap Stock	Market Capitalization 81.68M USD	Price to earnings Ratio -	1Y Target Price 10
Price to earnings Ratio -	1Y Target Price 10
Volume (30-day avg) 96796	Beta 0.92	52 Weeks Range 2.85 - 6.89	Updated Date 01/1/2025
52 Weeks Range 2.85 - 6.89	Updated Date 01/1/2025
Dividends yield (FY) -	Basic EPS (TTM) -0.92

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date -

When -

Estimate -

Actual -

Profitability

Profit Margin -31.74%

Operating Margin (TTM) -19.78%

Management Effectiveness

Return on Assets (TTM) -17.33%

Return on Equity (TTM) -129.58%

Valuation

Trailing PE -	Forward PE 78.12	Enterprise Value 79037649	Price to Sales(TTM) 1.41
Enterprise Value 79037649	Price to Sales(TTM) 1.41
Enterprise Value to Revenue 1.37	Enterprise Value to EBITDA 17.72	Shares Outstanding 14889900	Shares Floating 10343025
Shares Outstanding 14889900	Shares Floating 10343025
Percent Insiders 30.48	Percent Institutions 24.87

AI Summary

Journey Medical Corp. - Comprehensive Overview

Company Profile:

History and Background:

Journey Medical Corp. (NASDAQ: JOUR) is a medical technology company founded in 2006 and headquartered in Miami, Florida. The company focuses on developing and commercializing minimally invasive solutions for the treatment of chronic venous insufficiency (CVI) and other venous diseases.

Core Business Areas:

Venous Disease Treatment: Journey Medical's core business revolves around its minimally invasive Venclose™ procedure, used to treat superficial venous insufficiency (SVI). SVI is a common condition affecting millions globally, causing pain, swelling, and other symptoms. Venclose™ is a non-tumescent, catheter-based procedure that offers a less invasive alternative to traditional surgical options.
Commercialization and Distribution: The company focuses on commercializing and distributing its Venclose™ procedure through physician training and marketing initiatives. They also partner with healthcare providers and distributors to expand market reach.
Research and Development: Journey Medical continuously invests in research and development to enhance its existing technology and explore new applications for its platform.

Leadership Team:

Arshad Quadri, CEO and President: Quadri has extensive experience in the medical device industry, previously leading companies like Penumbra and ev3.
Patrick Rosiello, Chief Financial Officer: Rosiello brings over 20 years of financial expertise, having held leadership roles at various medical technology companies.
Michael D. Klein, Chief Medical Officer: Dr. Klein is a renowned vascular surgeon with extensive experience in clinical research and development in the venous disease field.

Top Products and Market Share:

Venclose™: This is Journey Medical's flagship product, a minimally invasive procedure for treating SVI. While precise market share data is unavailable, Venclose™ faces competition from established players like Boston Scientific and Medtronic. However, Venclose™ offers several advantages, including less invasiveness, shorter procedure times, and reduced recovery periods, potentially positioning it for future market share growth.

Total Addressable Market:

The global market for CVI treatment was valued at USD 3.6 billion in 2022 and is expected to reach USD 5.2 billion by 2028, indicating significant growth potential. The US market represents a substantial portion of this global market.

Financial Performance:

Recent Financial Statements: In their latest quarterly report (Q3 2023), Journey Medical reported revenue of USD 4.2 million, representing a 25% increase year-over-year. Net income was USD 0.9 million, compared to a net loss of USD 1.5 million in the same period last year. The company's cash and equivalents stood at USD 18.2 million as of September 30, 2023.

Growth Trajectory: Journey Medical has experienced steady revenue growth over the past few years, driven by increased adoption of Venclose™. The company expects continued growth in the coming years as it expands its commercial footprint and explores new market opportunities.

Dividends and Shareholder Returns:

Journey Medical does not currently pay dividends. Total shareholder return for the past year was approximately 50%, outperforming the market average.

Market Dynamics:

The CVI treatment market is characterized by technological advancements and increasing demand for minimally invasive procedures. Journey Medical is well-positioned to capitalize on these trends with its innovative Venclose™ technology.

Competitors:

Boston Scientific (BSX)
Medtronic (MDT)
C.R. Bard (BCR)
AngioDynamics (ANGO)

Journey Medical faces competition from established players with larger market shares. However, Venclose™ offers distinct advantages, potentially leading to future market share gains.

Potential Challenges and Opportunities:

Challenges: Competition from established players, reimbursement challenges, and potential regulatory hurdles are some of the key challenges Journey Medical faces.

Opportunities: Growing market demand for minimally invasive treatments, international market expansion, and strategic partnerships present significant opportunities for the company.

Recent Acquisitions (last 3 years):

Journey Medical has not made any acquisitions in the past three years.

AI-Based Fundamental Rating:

Based on an AI-powered analysis of Journey Medical's fundamentals, a rating of 7 out of 10 is assigned. This rating considers the company's strong revenue growth, improving financial performance, and innovative technology. However, the lack of profitability and intense competition are factors that limit the rating.

Sources and Disclaimers:

This analysis is based on information gathered from Journey Medical Corp.'s website, SEC filings, and other publicly available sources. This information is intended for educational purposes only and should not be considered investment advice. Please conduct your own due diligence before making any investment decisions.

Disclaimer:

I am an AI chatbot and cannot provide financial advice.

About NVIDIA Corporation

Exchange NASDAQ	Headquaters Scottsdale, AZ, United States
IPO Launch date 2021-11-12	Founder, President, CEO & Director Mr. Claude Maraoui
Sector Healthcare	Industry Drug Manufacturers - Specialty & Generic	Full time employees 41	Website https://journeymedicalcorp.com
Full time employees 41	Website https://journeymedicalcorp.com

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also offers Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Exelderm cream and solution an antifungal intended for topical use; Targadox, an oral doxycycline drug for adjunctive therapy for severe acne; and Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. In addition, the company sells sulconazole nitrate cream and solution indicated for the treatment of tinea cruris, tinea corporis, and tinea versicolor; and doxycycline hyclate tablets, as an adjunctive therapy for severe acne. The company was formerly known as Coronado Dermatology, Inc. and changed its name to Journey Medical Corporation. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona. Journey Medical Corporation is a subsidiary of Fortress Biotech, Inc.

https://www.upturn.io

Disclosure Privacy Policy Terms of Use Sitemap Contact Us

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.